Targretin (Page 4 of 4)

OVERDOSAGE

Systemic toxicity following acute overdosage with topical application of Targretin® gel is unlikely because of low systemic plasma levels observed with normal therapeutic doses. There is no specific antidote for overdosage.

There has been no experience with acute overdose of Targretin® gel in humans. Any overdose with Targretin® gel should be treated with supportive care for the signs and symptoms exhibited by the patient.

DOSAGE AND ADMINISTRATION

Targretin® gel should be initially applied once every other day for the first week. The application frequency should be increased at weekly intervals to once daily, then twice daily, then three times daily and finally four times daily according to individual lesion tolerance. Generally, patients were able to maintain a dosing frequency of two to four times per day. Most responses were seen at dosing frequencies of two times per day and higher. If application site toxicity occurs, the application frequency can be reduced. Should severe irritation occur, application of drug can be temporarily discontinued for a few days until the symptoms subside. See CONTRAINDICATIONS: Pregnancy: Category X.

Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry before covering with clothing. Because unaffected skin may become irritated, application of the gel to normal skin surrounding the lesions should be avoided. In addition, do not apply the gel near mucosal surfaces of the body.

A response may be seen as soon as 4 weeks after initiation of therapy but most patients require longer application. With continued application, further benefit may be attained. The longest onset time for the first response among the responders was 392 days based on the Composite Assessment of Index Lesion Severity in the multicenter study. In clinical trials, Targretin® gel was applied for up to 172 weeks.

Targretin® gel should be continued as long as the patient is deriving benefit.

Occlusive dressings should not be used with Targretin® gel.

Targretin® gel is a topical therapy and is not intended for systemic use. Targretin® gel has not been studied in combination with other CTCL therapies.

HOW SUPPLIED

Targretin® gel is supplied in tubes containing 60 g (600 mg active bexarotene).

60 g tube ………………………………………………………………………………… NDC 64365-504-01

Store at 25°C (77°F); with excursions permitted to 15°-30°C (59°-86°F) [see USP]. Avoid exposing to high temperatures and humidity after the tube is opened. Protect from light.

Manufactured for: Ligand Pharmaceuticals Incorporated
San Diego, CA 92121

by: Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

Ligand Part #3000204 (Rev. 0101)

TARGRETIN
bexarotene gel
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:64365-504
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
bexarotene (bexarotene) bexarotene 10 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
dehydrated alcohol
polyethylene glycol 400
hydroxypropyl cellulose
butylated hydroxytoluene
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:64365-504-01 60 g (60 GRAM) in 1 TUBE None
Labeler — Ligand Pharmaceuticals Inc.

Revised: 03/2006 Ligand Pharmaceuticals Inc.

Page 4 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.